Brian Kushner
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Brian Kushner as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06528496 · N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaMemorial Sloan Kettering Cancer Center · recruiting · High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma · principal investigator
- Ph2NCT06057948 · A Study of a Vaccine in Combination With Beta-glucan in People With NeuroblastomaMemorial Sloan Kettering Cancer Center · recruiting · Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma · principal investigator
- Early Ph1NCT04947501 · A Study of N9 Chemotherapy in Children With NeuroblastomaMemorial Sloan Kettering Cancer Center · active not recruiting · Neuroblastoma, Pediatric Cancer · principal investigator
- Ph2NCT04936529 · A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With NeuroblastomaMemorial Sloan Kettering Cancer Center · recruiting · Neuroblastoma · principal investigator
- N/ANCT04501757 · Naxitamab and GM-CSF in People With NeuroblastomaMemorial Sloan Kettering Cancer Center · no longer available · High-Risk Neuroblastoma · principal investigator
- N/ANCT02100930 · Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
- Ph1/Ph2NCT01757626 · Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · active not recruiting · Neuroblastoma · principal investigator
- Ph2NCT01183897 · 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone MarrowMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
- Ph2NCT01183884 · 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · terminated · Neuroblastoma · principal investigator
- Ph2NCT01183416 · High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell TransplantationMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
- Ph2NCT01183429 · 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
- Ph1/Ph2NCT00911560 · Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:14 UTC. The ranking covers the 200 most relevant of 54 PubMed records, and a shared surname and initials can bring in a namesake. All 54 on PubMed
- Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.J Clin Oncol · 1996276 citationsRCR 7.6
- 214 citationsRCR 5.6
- Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.J Clin Oncol · 2001161 citationsRCR 3.3
- Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.J Clin Oncol · 1998153 citationsRCR 3.6
- Selective surgery for intermittent exotropia based on distance/near differences.Arch Ophthalmol · 1998147 citationsRCR 8.6
- Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.J Clin Oncol · 1995136 citationsRCR 4.6
- Congenital nasolacrimal system obstruction.Arch Ophthalmol · 1982135 citationsRCR 10.6
- Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.J Clin Oncol · 2003130 citationsRCR 3.2
- 115 citationsRCR 3.1
- 111 citationsRCR 3.7